keyword
MENU ▼
Read by QxMD icon Read
search

clinical oncology

keyword
https://www.readbyqxmd.com/read/29457984/cardio-oncology-the-role-of-advanced-echocardiography-in-cancer-patients
#1
Lucia Venneri, Giacomo Zoppellaro, Rajdeep S Khattar
Cardio-oncology is a rapidly growing field aimed at improving the quality of care of cancer patients by preventing and monitoring cardiovascular complications resulting from cancer treatment. Cardiac imaging, and in particular, transthoracic echocardiography, plays an essential role in the baseline assessment and serial follow-up of cardio-oncology patients. Areas covered: This review article discusses the role of cardiac imaging with a focus on advanced echocardiography for the detection and management of cancer therapy related cardiovascular complications, in particular, left ventricular dysfunction and heart failure...
February 19, 2018: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/29456848/survival-associated-factors-of-first-line-egfr-tyrosine-kinase-inhibitor-responders-and-non-responders-in-lung-adenocarcinoma-patients-with-common-egfr-mutations
#2
Ming-Szu Hung, Yu-Hung Fang, Yu-Ching Lin, Jr-Hau Lung, Meng-Jer Hsieh, Ying-Huang Tsai
The aim of the present retrospective cohort study was to elucidate the clinical presentation of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) responders and non-responders in lung adenocarcinoma patients with common EGFR mutations. The cohort included 131 lung adenocarcinoma patients with common exon 19 or exon 21 EGFR mutations, who were receiving first-line EGFR-TKI therapy. The patient characteristics, treatment regimen and outcomes were recorded and analyzed. Of the 131 patients, 104 (79...
March 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29456738/recurrence-of-adenoid-cystic-carcinoma-of-the-trachea-treated-with-radical-radiotherapy-a-case-report
#3
Konrad Pawlewicz, Zbigniew Szutkowski, Andrzej Kawecki
Adenoid cystic carcinoma (ACC) of the trachea is a relatively rare tumor among thoracic diseases. The present study reports the case of a 23-year-old woman with ACC of the trachea who underwent surgical resection of the tumor in The National Institute of Tuberculosis and Lung Diseases (Warsaw, Poland). Histopathological examination revealed that the tumor was not completely resected (R2 resection) and strict observation of the patient was therefore prescribed. After ~9 years of follow-up, clinical and histopathological tumor progression was confirmed and the patient was referred to the Centre of Oncology in Warsaw...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29456713/-in-vitro-study-on-the-role-of-sox9-in-trastuzumab-resistance-of-adenocarcinoma-of-the-esophagogastric-junction
#4
Yingcai Hong, Huaisheng Chen, Zhanpeng Rao, Bin Peng, Hong Hu, Shaolin Lin, Zhenglei Xu
Trastuzumab is recommended for the treatment of human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagogastric junction (AEG) in combination with chemotherapy; however, drug resistance has severely affected its clinical application. The present study aimed to investigate the effect of sex determining region Y-box 9 (SOX9), a prognostic marker in adjuvant oncological settings, on AEG cell proliferation and apoptosis in the presence or absence of trastuzumab. Furthermore, the molecular mechanism underlying the role of SOX9 in trastuzumab resistance was explored...
March 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29456622/does-the-oncology-community-have-a-rejection-bias-when-it-comes-to-repurposed-drugs
#5
EDITORIAL
Bishal Gyawali, Pan Pantziarka, Sergio Crispino, Gauthier Bouche
Among the various measures proposed to combat the challenge of financial toxicity in cancer care, an important strategy is the use of lower-priced drugs instead of expensive alternatives. However, the oncology community seems to either ignore or more readily reject cheaper drugs in cancer care compared to more expensive alternatives. In this commentary, we present three examples of lower-priced drugs rejected or ignored by the oncology community and contrast this with three expensive drugs where persistent optimism remained despite negative clinical trial results...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29455939/strategies-to-facilitate-shared-decision-making-about-pediatric-oncology-clinical-trial-enrollment-a-systematic-review
#6
REVIEW
Eden G Robertson, Claire E Wakefield, Christina Signorelli, Richard J Cohn, Andrea Patenaude, Claire Foster, Tristan Pettit, Joanna E Fardell
OBJECTIVE: We conducted a systematic review to identify the strategies that have been recommended in the literature to facilitate shared decision-making regarding enrolment in pediatric oncology clinical trials. METHODS: We searched seven databases for peer-reviewed literature, published 1990-2017. Of 924 articles identified, 17 studies were eligible for the review. We assessed study quality using the 'Mixed-Methods Appraisal Tool'. We coded the results and discussions of papers line-by-line using nVivo software...
February 11, 2018: Patient Education and Counseling
https://www.readbyqxmd.com/read/29455872/-pd-l1-expression-and-pd-1-pd-l1-inhibitors-in-breast-cancer
#7
REVIEW
Audrey Monneur, Anthony Gonçalves, François Bertucci
The development of immune checkpoints inhibitors represents one of the major recent advances in oncology. Monoclonal antibodies directed against the programmed cell death protein 1 (PD-1) or its ligand (PD-L1) provides durable disease control, particularly in melanoma, lung, kidney, bladder and head and neck cancers. The purpose of this review is to synthesize current data on the expression of PD-L1 in breast cancer and on the preliminary clinical results of PD-1/PD-L1 inhibitors in breast cancer patients. In breast cancer, PD-L1 expression is heterogeneous and is generally associated with the presence of tumor-infiltrating lymphocytes as well as the presence of poor-prognosis factors, such as young age, high grade, ER-negativity, PR-negativity, and HER-2 overexpression, high proliferative index, and aggressive molecular subtypes (triple negative, basal-like, HER-2-overexpressing)...
February 15, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29455673/kinase-targeted-cancer-therapies-progress-challenges-and-future-directions
#8
REVIEW
Khushwant S Bhullar, Naiara Orrego Lagarón, Eileen M McGowan, Indu Parmar, Amitabh Jha, Basil P Hubbard, H P Vasantha Rupasinghe
The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein-coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer...
February 19, 2018: Molecular Cancer
https://www.readbyqxmd.com/read/29455379/comparative-study-of-different-classification-models-in-renal-cell-carcinoma
#9
Alejandro José Sastre-Heres, Irene Iglesias, Miguel Alaguero-Calero, Daniel Ruiz-Sánchez, Benito García-Díaz, Jaime Peña-Díaz
The aim of this study was to compare the Memorial Sloan-Kettering Cancer Center (MSKCC) and the Cleveland Clinic Foundation (CCF) models of classification of aRCC patients. In addition, the model developed from the pivotal trial of temsirolimus and those proposed by Motzer et al. in 2004, Escudier et al., Heng et al., Choueiri et al. and Bamias et al. were examined. An observational, retrospective study of patients starting first-line systemic therapy was conducted between 2008 and 2011. The variables used to evaluate the classification models were median overall survival (mOS) and median progression-free survival (mPFS)...
February 17, 2018: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29454478/usefulness-of-integrating-heart-failure-risk-factors-into-impairment-of-global-longitudinal-strain-to-predict-anthracycline-related-cardiac-dysfunction
#10
M Wesley Milks, Michael R Velez, Nishaki Mehta, Abiodun Ishola, Thomas Van Houten, Vedat O Yildiz, Raquel Reinbolt, Maryam Lustberg, Sakima A Smith, David A Orsinelli
The prediction of cancer therapeutics-related cardiac dysfunction (CTRCD) is an essential aspect of care for individuals who receive potentially cardiotoxic oncologic treatments. Certain clinical risk factors have been described for incident CTRCD, and measurement of left ventricular (LV) longitudinal strain by speckle tracking 2-dimensional echocardiography (2DE) is the best-validated myocardial mechanical imaging assessment to detect subtle changes in LV function during cancer treatment. However, the direct integration of clinical and imaging risk factors to predict CTRCD has not yet been extensively examined...
January 12, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29454347/oncology-nurses-beliefs-and-attitudes-towards-the-double-check-of-chemotherapy-medications-a-cross-sectional-survey-study
#11
D L B Schwappach, Katja Taxis, Yvonne Pfeiffer
BACKGROUND: Double-checking medications is a widely used strategy to enhance safe medication administration in oncology, but there is little evidence to support its effectiveness. The proliferated use of double-checking may be explained by positive attitudes towards checking among nurses. This study investigated oncology nurses' beliefs towards double-checking medication, its relation to beliefs about safety and the influence of nurses' level of experience and proximity to clinical care...
February 17, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29454337/the-second-patient-family-members-of-cancer-patients-and-their-role-in-end-of-life-decision-making
#12
Katsiaryna Laryionava, Timo A Pfeil, Mareike Dietrich, Stella Reiter-Theil, Wolfgang Hiddemann, Eva C Winkler
BACKGROUND: Family members are important companions of severely ill patients with cancer. However, studies about the desirability and difficulties of integrating relatives in the decision-making process are rare in oncology. This qualitative study explores the family role in decisions to limit treatment near the end of life from the professionals' point of view. METHODS: Qualitative in-depth interviews were conducted with oncologists (n = 12) and nurses (n = 6) working at the Department of Hematology/Oncology at the University Hospital in Munich, Germany...
February 17, 2018: BMC Palliative Care
https://www.readbyqxmd.com/read/29453626/drug-approval-based-on-randomized-phase-3-trials-for-relapsed-malignancy-analysis-of-oncologic-drugs-granted-accelerated-approval-publications-and-clinical-trial-databases
#13
Sumimasa Nagai, Keiya Ozawa
Background As relapsed disease is frequently the first target of newly developed therapies, it is vital to address the difficulty in demonstrating the efficacy of new drugs for relapsed malignancy in randomized phase 3 trials. Methods We analyzed the approved indications, target populations, and development status of post-marketing confirmatory trials of all oncology-related drugs that were granted accelerated approval for both hematological and solid malignancies. Furthermore, we searched for randomized phase 3 trials for adult patients with relapsed lymphoid malignancy, other than chronic lymphocytic leukemia (CLL) and multiple myeloma (MM)...
February 17, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29453595/cardio-oncology-conflicting-priorities-of-anticancer-treatment-and-cardiovascular-outcome
#14
REVIEW
Lisa M Tilemann, Markus B Heckmann, Hugo A Katus, Lorenz H Lehmann, Oliver J Müller
BACKGROUND: This article about the emerging field of cardio-oncology highlights typical side effects of oncological therapies in the cardiovascular system, cardiovascular complications of malignancies itself, and potential preventive or therapeutic modalities. METHODS: We performed a selective literature search in PubMed until September 2016. RESULTS: Cardiovascular events in cancer patients can be frequently attributed to oncological therapies or to the underlying malignancy itself...
February 16, 2018: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29453505/does-hope-matter-associations-among-self-reported-hope-anxiety-and-health-related-quality-of-life-in-children-and-adolescents-with-cancer
#15
Ana Rita Martins, Carla Crespo, Ágata Salvador, Susana Santos, Carlos Carona, Maria Cristina Canavarro
This study aimed to examine the direct and indirect effects of hope on health-related quality of life (HRQoL) via anxiety of children/adolescents with cancer. We proposed to test if the mediation model was moderated by the child/adolescent's treatment status. The participants were 211 children/adolescents diagnosed with cancer, divided into two clinical groups according to treatment status: 97 patients on-treatment and 114 off-treatment. Self-reported questionnaires measured the youths' hope, anxiety, and HRQoL perceptions...
February 16, 2018: Journal of Clinical Psychology in Medical Settings
https://www.readbyqxmd.com/read/29453313/multigene-profiling-of-ctcs-in-mcrpc-identifies-a-clinically-relevant-prognostic-signature
#16
Udit Singhal, Yugang Wang, James Henderson, Yashar S Niknafs, Yuanyuan Qiao, Amy Gursky, Alexander Zaslavsky, Jae-Seung Chung, David C Smith, R Jeffrey Karnes, S Laura Chang, Felix Y Feng, Ganesh S Palapattu, Russell S Taichman, Arul M Chinnaiyan, Scott A Tomlins, Todd M Morgan
The trend towards precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer related genes...
February 16, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29453043/understanding-of-human-atp-binding-cassette-superfamily-and-novel-multidrug-resistance-modulators-to-overcome-mdr
#17
REVIEW
Imran Shair Mohammad, Wei He, Lifang Yin
Indeed, multi-drug resistance (MDR) is a significant obstacle to effective chemotherapy. The overexpression of ATP-binding cassette (ABC) membrane transporters is a principal cause of enhanced cytotoxic drug efflux and treatment failure in various types of cancers. At cellular level, the pumps of ABC family regulate the transportation of numerous substances including drugs in and out of the cells. In past, the overexpression of ABC pumps suggested a well-known mechanism of drug resistance in cancers as well as infectious diseases...
February 13, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29452837/dramatically-polarized-opinion-on-the-role-of-brachytherapy-boost-in-management-of-high-risk-prostate-cancer-a-survey-of-north-american-genitourinary-expert-radiation-oncologists
#18
Shearwood McClelland, Kiri A Sandler, Catherine Degnin, Yiyi Chen, Timur Mitin
INTRODUCTION: Three randomized clinical trials have established brachytherapy (BT) boost in combination with external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT) as superior to definitive EBRT and ADT alone in terms of biochemical control (but not overall survival) at the expense of increased toxicity in men with high-risk (HR) prostate cancer (PCa). The current view regarding these 2 treatment algorithms among North American genitourinary (GU) experts is not known...
February 2, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29452548/oncology-clinical-pathways-a-form-of-governance
#19
Peter Paul Yu
No abstract text is available yet for this article.
February 8, 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29451420/integration-of-clinical-pharmacists-into-an-ambulatory-pediatric-hematology-oncology-transplant-clinic
#20
Kimberly D Defoe, Jennifer Jupp, Tara Leslie
Objectives To describe key activities performed by a newly deployed clinical pharmacist in an outpatient pediatric hematology, oncology, transplant clinic. To demonstrate how utilization of the pharmacist evolved, as indicated by changes in frequency of key activities, during the first four months of integration. Design Clinical pharmacists were made consistently available in an outpatient clinic serving hematology, oncology, transplant patients and their families. A list of key activities, based on provincial clinical pharmacist standards, was created to provide a framework for the role...
January 1, 2018: Journal of Oncology Pharmacy Practice
keyword
keyword
85701
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"